(Q38385536)

English

Safety of ASP0113, a cytomegalovirus DNA vaccine, in recipients undergoing allogeneic hematopoietic cell transplantation: an open-label phase 2 trial

scientific article published on 28 October 2016

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Safety of ASP0113, a cytomegalovirus DNA vaccine, in recipients undergoing allogeneic hematopoietic cell transplantation: an open-label phase 2 trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

phase II clinical trial

0 references

author name string

Takehiko Mori

1

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Yoshinobu Kanda

2

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Katsuto Takenaka

3

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Shinichiro Okamoto

4

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Jun Kato

5

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Junya Kanda

6

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Goichi Yoshimoto

7

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Hisashi Gondo

8

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Sayaka Doi

9

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Masaki Inaba

10

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Yoshihisa Kodera

11

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

publication date

28 October 2016

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

International Journal of Hematology

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

105

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

206-212

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Seroprevalence of cytomegalovirus IgG antibodies among pregnant women in Japan from 2009-2014.

1 reference

https://api.crossref.org/works/10.1007%2FS12185-016-2110-3

21 January 2018

Changes in cytomegalovirus seroprevalence in pregnant Japanese women-a 10-year single center study

1 reference

https://api.crossref.org/works/10.1007%2FS12185-016-2110-3

21 January 2018

Therapeutic strategies for cytomegalovirus in allogeneic hematopoietic cell transplantation

1 reference

https://api.crossref.org/works/10.1007%2FS12185-016-2110-3

21 January 2018

Cytomegalovirus in hematopoietic stem cell transplant recipients

1 reference

https://api.crossref.org/works/10.1007%2FS12185-016-2110-3

21 January 2018

The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy

1 reference

https://api.crossref.org/works/10.1007%2FS12185-016-2110-3

21 January 2018

Antiviral treatment of cytomegalovirus infection

1 reference

https://api.crossref.org/works/10.1007%2FS12185-016-2110-3

21 January 2018

Antiviral drugs for cytomegalovirus diseases

1 reference

https://api.crossref.org/works/10.1007%2FS12185-016-2110-3

21 January 2018

A DNA-based vaccine for the prevention of human cytomegalovirus-associated diseases

1 reference

https://api.crossref.org/works/10.1007%2FS12185-016-2110-3

21 January 2018

Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects

1 reference

https://api.crossref.org/works/10.1007%2FS12185-016-2110-3

21 January 2018

Vaccine therapy for cytomegalovirus in the setting of allogeneic hematopoietic cell transplantation

1 reference

https://api.crossref.org/works/10.1007%2FS12185-016-2110-3

21 January 2018

A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial.

1 reference

https://api.crossref.org/works/10.1007%2FS12185-016-2110-3

21 January 2018

Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects

1 reference

https://api.crossref.org/works/10.1007%2FS12185-016-2110-3

21 January 2018

Definitions of cytomegalovirus infection and disease in transplant recipients

1 reference

https://api.crossref.org/works/10.1007%2FS12185-016-2110-3

21 January 2018

Efficiency and risk factors for CMV transmission in seronegative hematopoietic stem cell recipients

1 reference

https://api.crossref.org/works/10.1007%2FS12185-016-2110-3

21 January 2018

Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections

1 reference

https://api.crossref.org/works/10.1007%2FS12185-016-2110-3

21 January 2018

Preventing opportunistic infections after hematopoietic stem cell transplantation: the Centers for Disease Control and Prevention, Infectious Diseases Society of America, and American Society for Blood and Marrow Transplantation Practice Guidelines

1 reference

https://pubmed.ncbi.nlm.nih.gov/27796740

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Complications, diagnosis, management, and prevention of CMV infections: current and future

1 reference

https://pubmed.ncbi.nlm.nih.gov/27796740

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identification of the human cytomegalovirus glycoprotein B gene and induction of neutralizing antibodies via its expression in recombinant vaccinia virus.

1 reference

https://pubmed.ncbi.nlm.nih.gov/27796740

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity

1 reference

https://pubmed.ncbi.nlm.nih.gov/27796740

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

VCL-CB01, an injectable bivalent plasmid DNA vaccine for potential protection against CMV disease and infection

1 reference

https://pubmed.ncbi.nlm.nih.gov/27796740

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Viral infections in transplant recipients.

1 reference

https://pubmed.ncbi.nlm.nih.gov/27796740

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Strain-specific seroepidemiology and reinfection of cytomegalovirus

1 reference

https://pubmed.ncbi.nlm.nih.gov/27796740

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cytomegalovirus (CMV) seroprevalence in Japanese blood donors and high detection frequency of CMV DNA in elderly donors

1 reference

https://pubmed.ncbi.nlm.nih.gov/27796740

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nephrotoxicity of antiviral therapies

1 reference

https://pubmed.ncbi.nlm.nih.gov/27796740

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S12185-016-2110-3

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38385536&oldid=2201644222"